O'Loughlin Steve 4
4 · Actinium Pharmaceuticals, Inc. · Filed Jul 1, 2022
Insider Transaction Report
Form 4
O'Loughlin Steve
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2022-07-01+256,438→ 256,348 totalExercise: $4.96Exp: 2032-07-01→ Common Stock (256,438 underlying)
Footnotes (2)
- [F1]This price represents the closing price of the Company's common stock on July 1, 2022, the date of the grant.
- [F2]Pursuant to the terms of the Company's 2019 Stock Plan, 2% of the options will vest each month from July 1, 2022 until fully vested.